Big Pharma ramping up China R&D ops

Drug discovery and research activities have traditionally focused on diseases common in the U.S. and Europe. That is, after all, where the money is. But as Reuters expounds on in an analysis out today, China is grabbing an increasing share of the global R&D budget, with investigators launching a slew of new studies to help understand how to treat the country's huge population and tap into one of the fastest growing pharma markets on the planet. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.